M.D. Anderson Cancer Center
This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection.
Primary Objectives: Phase I To evaluate the feasibility and safety of radiation therapy with NBTXR3 in LA-NSCLC with the following dose escalation: * 45 Gy in 15 fx with NBTXR3 at 22% RP2D * 52.5 Gy in 15 fx with NBTXR3 at 22% RP2D * 60 Gy in 15 fx with NBTXR3 at 22% RP2D * 60 Gy in 15 fx with NBTXR3 at 33% RP2D Phase II * To estimate the efficacy of radiation therapy alone with NBTXR3 in inoperable, locoregional NSCLC * To evaluate the safety of RP2D Secondary Objectives: * To evaluate the anti-tumor response of radiation with NBTXR3 in patients with inoperable, locoregional NSCLC * To…
Inclusion Criteria: 1. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. 2. Age ≥ 18 years. 3. ECOG Performance Status 0-2 4. Biopsy proven stage I-III NSCLC. 5. Participant deemed medically inoperable by the investigator or treating physician, or patient declines surgery. 6. No prior or concurrent systemic therapies within 4 weeks of injection. Patient may receive up to 1 line of prior systemic therapy prior to starting RT. 7. Amenable to undergo bronchoscopic (EBUS, CB…
Given by injection
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.